WILL PFE BUY CELSIONS DUKE LICENSE FOR LTSL DRUG DELIVERY?
There have been rumblings of late to that effect. This liposomally encapsulated, heat activated drug delivery platform delivers drugs from the "inside out". A distinct advantage when dealing with tumors of all sizes and shapes. This could be our next PIPELINE of PIPLELINES . Furthermore, the cost of acquisition would be relatively CHEAP (less than 1 Billion)